Small RNA sequencing of endometrial cancer patients with samples collected prior to diagnosis and controls

• HMB DUO:0000006 (version: 2021-02-23)health or medical or biomedical researchThis data use permission indicates that use is allowed for health/medical/biomedical purposes; does not include the study of population origins or ancestry.
• COL DUO:0000020 (version: 2021-02-23)collaboration requiredThis data use modifier indicates that the requestor must agree to collaboration with the primary study investigator(s).
• IRB DUO:0000021 (version: 2021-02-23)ethics approval requiredThis data use modifier indicates that the requestor must provide documentation of local IRB/ERB approval.
• TS DUO:0000025 (version: 2021-02-23)time limit on useThis data use modifier indicates that use is approved for a specific number of months.
• PS DUO:0000027 (version: 2021-02-23)project specific restrictionThis data use modifier indicates that use is limited to use within an approved project.
• IS DUO:0000028 (version: 2021-02-23)institution specific restrictionThis data use modifier indicates that use is limited to use within an approved institution.

Norwegian Institute of Public Health – Cancer Registry of Norway Data Access Policy for JanusRNA transcriptomics datasets archived in Federated EGA Norway

1. Processing of access requests Data access requests to the JanusRNA transcriptomics datasets are processed according to the detailed descriptions available from the JanusRNA website: ● https://www.kreftregisteret.no/en/Research/Projects/Identification-of-early-cancer-biomarkers/ ● Contact details to the JanusRNA Data Access Committee (defined below), as well as required information needed and how to provide it is specified in this website. Please also make sure the Data Use Conditions (defined below) for this dataset as annotated in FEGA Norway allows for your intended application of the data, and that you understand there are legal agreements needed for data access to be granted (explained below). 2. Data Access Committee A Data Access Committee (DAC) is a body of one or more named individuals who are responsible for data release to external requesters based on consent and/or National Research Ethics terms. Each dataset submitted by Norwegian Institute of Public Health – Cancer Registry of Norway (CRN) for archival and controlled access sharing in Federated EGA Norway, has a DAC appointed by CRN to govern controlled access to the dataset according to this Data Access Policy. Multiple datasets may be affiliated to a single DAC. CRN as an institution has the overall data controller responsibility, and has appointed a DAC based on internal procedures that ensures involvement of institutional functions such as Data Protection Officer, legal division, etc. 3. Data use conditions To advise any would-be requester on how the data can be used, Data Use Ontology codes (DUO) is associated to each dataset, providing the requester more insights into which terms for sharing and use of the data that applies, and that needs to be addressed as part of the communication with the DAC in a data access request. No access to a CRN dataset deposited in FEGA Norway can be granted to a requester before all applicable conditions and requirements for the use and management of the data have been agreed upon in a signed Data Access Agreement. 4. Data Access Agreement The Data Access Agreement (DAA) will include requirements specific for both the dataset and the management of the data in the hands of the requester applying for access, and will thus be an individual DAA for each case of granted access to a dataset. As a rule, a DAA for an CRN dataset will take the form of a Data Transfer Agreement, where the requester will commit to take on responsibilities and duties as a data controller.